

Index

Page numbers in *italics* refer to examples in the text.

- active control studies, 282
- adaptive designs, *see* randomised controlled trials (RCTs)
- adverse drug reactions, 244, 255
- allocating subjects between phase II and III studies, 244
- alternative hypothesis, 31, 190
- anakinra (treatment for sepsis), 313
- Anscombe, F., 126, 127
- Armitage, P., 203

- B-14 trial, 219
- backwards induction, 90, 220
- Baigent, C., 139
- bandit problems, 235
- baseline rates, models for, 280
- Basis initiative, 113
- Bayes factor
 - and composite hypotheses, 55, 130–32
 - and lump-and-smear priors, 161
 - approximation, 131
 - as alternative to *P*-values, 130
 - for two simple hypotheses, 54–5, 128
 - from trial results, 75
 - in preference studies, 133
 - in urokinase trial, 164
 - Jeffreys' calibration of, 55
 - minimum, 30
 - transforms prior to posterior odds, 55
- Bayes theorem, 1–2
 - and interpreting trial results, 69–70, 74
 - definition and proof, 12–13
 - for binary data, 57, 59–60
 - for general quantities, 57
 - for random variables, 14
 - for simple events, 13
 - for two hypotheses, 51–2
 - in diagnostic testing, 52–3
 - normal data, 62–3
 - odds form, 13
 - sequential use, 79
- Bayes, Thomas, 1
- Bayesian approach
 - as formalisation of learning process, 2
 - caution needed, 3
 - description of, 3
 - different schools of, 112
 - future developments, 35
 - general advantages, 3, 349
 - generic problems, 350
 - importance of probability distributions, 9
 - origins of, 2
 - overview, 49–121
 - reporting, *see* reporting Bayesian analyses
 - software, 353
 - websites, 353
- Bernoulli, J., 57, 50
- Bernoulli distribution
 - definition, 57
 - example of use of, 18, 58
- Bernoulli trial, 57
- Berry, D., 182, 187
- beta distribution
 - as conjugate prior with binary data, 60
 - as prior for proportion, 60–1, 82, 108, 294
 - assessing parameters for, 60–1
 - definition and uses, 36–7

- beta-binomial distribution
 - definition, 81
 - for prediction, 82, 108
- between-group standard deviation, *see*
 - random-effects variability
- bias modelling
 - in evidence synthesis, 287, 330
 - in prior, 150
 - using quality weights, 332
 - with historical controls, 228, 231
 - with historical data, 90
 - with observational studies, 253, 257
- binary data
 - and Bayes theorem, 57
 - and prediction, 81
 - normal approximation to likelihood, 23
- binomial distribution, 81, 108, 128, 133
 - definition and uses, 34–5
- bivariate normal distribution
 - definition and uses, 44
 - for mean costs and benefits, 313, 314
- Bletchley Park, 52
- blood pressure, 283
- Bowley, A., 123
- Box's measure of conflict, 174, 199, 272
- breakeven point, 279
- Burton, P., 69

- CALGB trial, 224
- cancer prognosis, 12, 13–14
- case-control studies, 252, 255
- Chaloner, K., 142, 188
- CHART trials
 - clinical prior distribution, 144
 - criticism of prior, 176
 - monitoring, 207
 - range of equivalence, 185
 - sceptical prior distribution, 160
- checklist for Bayesian analyses, 113
- chi-squared distribution
 - Q test for heterogeneity, 93
 - definition, 39
- classical inference, 31
 - and sample size, 190
 - comparison of methods, 121
 - criticisms of, 123–4
 - hybrid with Bayesian, 193
 - interim predictions, 213
 - limitations of, 2
 - sample size, 32
- Claxton, K., 341, 342
- cluster randomisation, 227
- coherent probabilities, 50
- cohort database, 252
- Cole, P., 127
- community of priors, 139
 - and sensitivity analysis, 166
- comprehensive decision modelling, 328
- computational issues, 102
- conditional expectation, 17
- conditional independence, 18
 - in sequential use of Bayes theorem, 79
 - when making predictions, 81
- conditional likelihood
 - in meta-analysis, 274
 - to eliminate nuisance parameters, 101
- conditional power given interim data, *see*
 - interim power
- conditional probability, 11
- conditional variance, 17
- confidence interval, 31, 67
 - interpretation of, 123
- confidence profile method, 253, 268
- confirmatory studies, 224
- conjugate analysis
 - beta-binomial, 60
 - normal-normal, 62–3
- conjunction fallacy, 140
- CONSORT guidelines, 113
- context
 - of evaluation, 49
 - and cost-effectiveness analysis, 307
- continual reassessment method, 242, 242
- continuous responses, normal likelihood
 - for, 31
- Cornfield, J., 123, 127, 227
- correlation, 16, 314
- cost-effectiveness analysis, 305–348
 - and decision theory, 89
 - complex models, 322–335
 - cost-effectiveness acceptability curve (CEAC), 313
 - cost-effectiveness plane, 308
 - Crystal Ball software, 311
 - deterministic sensitivity analysis, 311, 321
 - discrete-time, discrete-state Markov models, 322
 - domination, 308
 - evidence synthesis, 329
 - expected net benefit from sampling (ENBS), 341
 - expected value of perfect information (EVPI), 337

- 'first-order' uncertainty, 321
- heterogeneity, 321
- incremental cost-effectiveness ratio (ICER), 308
- incremental net benefit (INB), 309, 312, 314, 319, 337, 340
- incremental net health benefit (INB*), 309
- integrated and two-stage approaches compared, 335
- integrated approach, 311
- integrated approach with single study, 315–319
- levels of uncertainty, 320
- Markov models, 322
- meta-analysis, 329
- micro-simulation, 323, 324
- model uncertainty, 321
- parameter uncertainty, 321
- partial expected value of perfect information (PEVPI), 341
- probabilistic sensitivity analysis, 310, 324
- probability of net benefit, 323
- 'second-order' uncertainty, 321
- two-stage approach, 310
- two-stage approach with single study, 312–314
- value of perfect information (VPI), 337
- willingness to pay, 308
- WinBUGS, 311
- count responses, 30
- covariance, 16
- Cox regression, 30
 - likelihood based on, 198
- Cox, D.R., 122
- credibility analysis, 75, 77, 99
- credible interval
 - comparison with confidence intervals, 65
 - for normal posterior, 68–9
 - highest posterior density, 65
 - interpretation, 66
 - one-sided, 65
 - two-sided, 65
- cross-design synthesis, *see* evidence synthesis
- crossover trials, 237
- Crystal Ball software, 311
- data monitoring committee, 176
 - Bayesian approach, 223
 - in B-14 trial, 216
 - in CHART trials, 210
- data-dependent allocation in RCTs, 235
- databases and RCTs, 187
- de Finetti, B., 56
- de Finetti's theorem, 56
- decision theory, 85
 - as 'full' Bayesian approach, 112
 - comparison of methods, 121
 - conflicting views on, 342
 - cost-effectiveness analysis, 341
 - for monitoring trials, 220
 - in phase II/III trials, 224
 - in RCTs, 182
 - in sample-size assessment, 193
 - irrelevance of measures of uncertainty, 91, 183
 - loss function, 89
 - multiple treatments in RCTs, 228
 - neural tube defects, 87
 - number needed to treat (NNT), 87
 - policy, 341
 - regret, 86
 - regulation, 341, 342
 - sequential trials, 204
 - state of nature, 86
 - utility, 86
- default prior distribution, *see* reference prior distribution
- DeMets, D., 203
- design, 90
- diagnostic testing, 52
- dice, 11, 50
- discount rates, 323, 333
- discounting previous studies, *see* historical evidence
- discrete-time, discrete-state Markov models, 322
- DoodleBUGS, 108
- dose-finding study, 236
- DuMouchel prior
 - for random-effects variability, 173, 273
- dynamic programming, 90, 220
- ECMO trial, 231
- Edgeworth, F., 51
- effective number of events, 25, 30, 73, 79, 256
- Eghtesady, P., 336
- electronic foetal heart monitoring, 275
- empirical Bayes approach, 94, 112
- Enigma codes, 52

- enoxaparin (Lovenox), 343
- enthusiastic prior distribution, *see* prior distribution
- equivalence trials, 237
- ethics and randomisation, 187
- evidence synthesis, 267–303
 - and cost-effectiveness analysis, 329
 - and modelling, 285, 288, 292, 294
 - cross-design, 285
 - functional dependence, 287
 - generalised, 285
 - quality weights, 331
- exchangeability, 92
 - and historical data, 148
 - and subset analysis, 227
 - basic concept, 56
 - in evidence synthesis, 285
 - judgement of and hierarchical models, 167
 - of historical controls in RCTs, 228
 - of random quantities, 56
 - of sample variances, 238, 317
 - of study effects, 284
- expectation, 16
 - conditional, 17, 312
 - iterated, 17, 81, 84
- expected net benefit from sampling (ENBS), 341
- expected power, *see* power
- expected value of perfect information (EVPI), 337
- 'extending the conversation', 12, 15
- factorial designs, 241
- Farewell, V., 122
- FAST[®] PRO software, 268
- Fayers, P., 148
- FDA Center for Devices and Radiological Health, 344
- Feinstein, A., 3
- 'first-order' uncertainty in
 - cost-effectiveness analysis, 321
- Fisher, R.A., 123
- Fisherian approach, 122
 - and sequential trials, 203
 - to sample size, 189
- frequentist inference, *see* classical inference
- function of parameters
 - example of inference on, 294, 298
- futility, *see* interim power, 211
- gamma distribution
 - as conjugate prior, 39
 - as prior for random-effects variability, 170
 - as prior for sample precisions, 238
 - definition and uses, 39
- gastric cancer trial
 - sample size, 197
- generalised evidence synthesis, *see* evidence synthesis
- graphical model, 292
 - in WinBUGS, 108
- GREAT trial
 - analysis of, 69–70
 - and sequential use of Bayes theorem, 79
 - Bayes factor in, 136
 - credibility analysis, 75
 - normal likelihood for, 27
 - prediction after, 84
 - prior criticism, 174
- Greenhouse, J., 112, 151, 158, 189
- group-sequential methods, 202
- GUSTO trial, 153
- half-normal distribution
 - as prior for normal mean, 163
 - as prior for random-effects variability, 168, 272, 289
 - definition and uses, 41
- hazard rate, 27
- hazard ratio, *see* log(hazard ratio)
- health-care evaluation, 3
- health-care interventions, 2
- health-technology assessments, 2
- Healy, M., 127, 182
- heterogeneity in cost-effectiveness analysis, 321
- hierarchical models
 - and evidence synthesis, 288
 - cluster randomisation, 227–8
 - for institutional comparisons, 259
 - for meta-analysis, 268
 - for sample variances, 238
 - hyperparameter estimation, 94
 - multi-centre analysis, 227
 - multiple endpoints, 228
 - multiple treatments, 228
 - normal distributions, 93
 - prior distributions, 167
 - prior for random-effects variance, *see* random-effects variability

- random-effects distribution for, 168
- shrinkage, 94
- subset analysis, 227
- highest posterior density interval, 65
- hindsight bias, 140
- hip replacement, 325, 331
- historical controls
 - exchangeability, 229
 - in ECMO trial, 231
 - modelling bias, 229
- historical evidence, 90, 148
 - about controls, 228
 - and prior distributions, 148
 - contexts, 6
 - discounted, 91, 151, 230, 286
 - functional dependence, 151
 - in evidence synthesis, 285
 - in observational studies, 253
 - possible relationships to current observations, 91
 - quality weights, 152
 - with potential biases, 150
- HIV, screening for, 339
- Hornberger, J., 336
- Hughes, M., 203
- hybrid classical and Bayesian approach, 190, 193
- hyperparameters, *see* hierarchical models
- hypertension, 279
- hypothesis testing
 - comparison of methods, 121
- in vitro* fertilisation, 259
- independent and identically distributed (i.i.d.), 17
- indirect comparison studies, 282
- indirect inference, 283
- inferences on many parameters, 91
- institutional comparisons, 258, 259
 - benefits of Bayesian approach, 259
- integration, importance of in Bayesian statistics, 16
- interim power
 - Bayesian, 212
 - classical, 213
 - curve, 212
 - hybrid classical and Bayesian approach, 211
- interval estimation, *see* credible interval
- interval hypotheses, 64, 67
- ISIS-4, 95, 131, 271
- iterated expectation, 16, 81, 84
- iterated variance, 16, 81, 84
- Jeffreys, H., 55
- K, willingness to pay, 308
- Kass, R., 112, 151, 158, 189
- key points
 - basic concepts from traditional analysis, 46
 - comparative inference, 136
 - cost-effectiveness analysis and policy, 345
 - evidence synthesis, 299
 - observational studies, 262
 - overview of Bayesian approach, 116
 - prior distributions, 176
 - randomised controlled trials, 245
- Laplace's law of succession, 82
- likelihood
 - ratio, 52, 54–55
 - and Bayes theorem, 57
 - Bernoulli, 19
 - definition, 18
 - description, 1–2
 - function, 18
 - interval estimates, 24
 - maximum likelihood estimate, 18
 - normal, *see* normal likelihood
 - profile, 94
 - supported parameter values, 18
- likelihood principle, 54, 124, 126
 - and sample size, 192
- Lindley's paradox, 135
- Lindley, D., 129, 182
- location, measures of, 63
- log(hazard ratio), 27–8
 - and survival probabilities, 28
 - approximate normal likelihood for, 30
 - example of inference on, 143, 160, 185, 194, 196, 198, 207, 215, 224
 - in power calculations, 32–33
- log-normal distribution
 - as prior for sample variances, 238, 317
 - definition and uses, 42–3
 - for costs, 317
- log(odds ratio)
 - approximate normal likelihood, 25
 - definition, 23
 - estimate of, 24–5

- log(odds ratio) (*cont.*)
 - example of inference on, 69, 77, 99, 136, 153, 175, 231, 255, 271, 275
- log-rank test statistic, 29–30
- log(rate ratio), 30
 - approximate normal likelihood for, 30
 - estimate of, 30
 - example of inference on, 279
 - variance of estimate, 30
- log(risk ratio), 23
 - example of inference on, 289
- logistic regression, 25
- logit, definition of, 13
- loss function, *see* decision theory, 182
- 'lump-and-smear' prior distribution, *see* prior distribution
- Macau, 50
- magnesium sulphate, 95, 271
- mammographic screening for breast cancer, 288
- Mantel–Haenszel analysis, 25
- maple syrup urine disease (MSUD), 292
- marginalisation, 11, 15
- Markov chain Monte Carlo methods
 - for calculating EVPI, 341
 - for ranking, 260
 - introduction, 105
- Markov models in cost-effectiveness analysis, 323, 325
- Matthews, R., 51
- maximising expected utility, 86
- maximum likelihood estimate, 19, 112
- MCMC, *see* Markov chain Monte Carlo methods
- mean, 17
- measurement error, 253
- Medical Decision Making*, 89
- Meier, P., 126
- meta-analysis, 268
 - adjustment for baseline rates, 280
 - advantages of Bayesian approach, 269
 - and cost-effectiveness analysis (CEA), 329
 - and prediction, 270
 - assessing compatibility with individual trials, 270
 - Bayesian interpretation of cumulative, 150
 - between-study variability, 274
 - cumulative, 271
 - 'empirical Bayes', 95
 - exact likelihoods, 274
 - nuisance parameters, 274, 275
 - of case–control studies, 255
 - prediction in new populations, 271
 - prediction on new trial, 270
 - publication bias, 271
 - relationship between treatment effect and underlying risk, 278
 - results on different scales, 269
 - with sceptical prior, 97
 - with studies of different types, 285
- method of moments, 94
- micro-simulation in cost-effectiveness analysis, 322
- minimax approach to decision-making, 89
- missing covariate data, 252
- mixed comparison studies, 282
- monitoring trials, 202
 - comparison of Bayesian and classical boundaries, 205
 - frequentist properties of Bayesian methods, 221
 - phase II, 243
 - using loss function, 220
 - using posterior distribution, 204
 - using predictions, 211, 214
 - using the posterior distribution, 207
- Monte Carlo methods, 103
 - in cost-effectiveness analysis, 310
 - in probabilistic sensitivity analysis, 105
 - predicting power, 202
- multi-centre analysis, 227
- multi-level model, 92
- multiple endpoints in RCTs, 228
- multiple treatments in RCTs, 228
- multiplicity, 91
 - and institutional comparisons, 259
 - and meta-analysis, 268
 - Bayesian approach to, 92
 - criticism of conventional approach, 127
 - in RCTs, 227
- N-of-1 trials, 237, 237
- National Institute of Clinical Excellence (NICE), 305
- Navajo children (influenza vaccine trial), 221
- neural tube defects, 87
- Neyman–Pearson approach, 122
 - and sample size, 189

- and sequential trials, 203
- criticisms of, 123
- non-informative prior distribution, *see* reference prior distribution
- normal approximations to likelihoods, 23
- normal distribution
 - and prediction, 82
 - as posterior, 62
 - as prior, 62
 - as prior for log(odds ratio), 69
 - as prior for normal mean, 62
 - definition, 20
 - difference, 22
 - distribution function, 20
 - in hierarchical models, 93
 - precision, 20
 - sum, 21
 - table of tail areas, 20
- normal likelihood
 - as approximation with nuisance parameters, 100, 101
 - and Bayes theorem, 62
 - applications of, 22
 - approximate for log(hazard ratio), 30
 - approximate for log(odds ratio), 26
 - approximate in GREAT trial, 26–7
 - approximations for binary data, 23
 - continuous responses, 31
 - count responses, 30
 - for survival data, 27
 - in classical inference, 31
 - in hierarchical models, 92
- normal mean
 - example of inference on, 163, 237, 283
- normal-normal conjugate analysis, 62–3
- nuisance parameters
 - in meta-analysis, 274, 275
 - methods for dealing with, 100–1
- null hypothesis, 31
 - in RCTs, 184
 - transforming power calculations, 196
- number needed to treat (NNT), 87, 88
- $O - E$, *see* observed minus expected
- O'Neill, R., 160
- O'Rourke, K., 166
- objective prior distribution, *see* reference prior distribution
- observational studies, 251–265
- observed – expected, 28
 - variance of, 29
- odds
 - definition, 12
 - odds ratio, *see* log(odds ratio)
- oral contraceptives, 255
- outcome measures, 23
 - binary, 23
 - continuous, 31
 - counts, 30
 - survival, 27
- P -values, 31–2, 122
 - criticism of use, 127–8
 - in sequential experiment, 124
 - irrelevance to decision-making, 90
- parametric distributions, 17
- partial expected value of perfect information (PEVPI), 341
- partition models, 92
- payback models, 335
- Pearson index, 336
- Pearson, E., 123
- perspectives of different stakeholders, 51
- Peto, R., 139, 183
- pharmacoepidemiology, 255
- pharmacokinetics, 242
- play-the-winner rule, 235
- Pocock, S., 147, 188, 203
- point estimation, 64
- Poisson distribution
 - definition and uses, 35
 - random-effects regression, 279
- policy-making, 305–47
- Posnett, J., 342
- posterior distribution
 - and Bayes theorem, 57
 - description, 1
 - in monitoring trials, 204
 - mean, median, mode, 64
 - normal, 62, 63–4
 - use in monitoring trials, 207
- posterior odds, 52
- power
 - and sample size, 189
 - Bayesian, 182, 194, 194, 196
 - changing null hypothesis, 196
 - classical, 31
 - conditional, 191
 - expected, 191, 196
 - hybrid classical and Bayesian approach, 193
 - incorporating prior information, 191, 198

power (*cont.*)

predictive distribution of, 201
with survival outcomes, 32

'power' prior distribution, *see* prior distribution

pre-natal HIV screening, 295

precision of normal distribution, 20

prediction, 80

and binary data, 81

and meta-analysis, 268

and normal distributions, 83

binary data, 108

increase in uncertainty, 84

of chance of 'significant' result, 211, 217

of power of an RCT, 201

preference studies, 128, 133

prior beliefs in medicine, 139

prior distribution, 139–180

and Bayes theorem, 57

and design, 139

and range of equivalence, 186

clinical, 141

community of,

comparison with observed data, 174

conjugate, 59–60, 139

default, *see* reference prior distribution

description, 1

discrete, 57

elicitation, *see* prior elicitation

empirical criticism of, 174

enthusiastic, 159, 160, 205

for normal mean, 63–4

for proportion, 60

for random-effects variance, *see* random-effects variability

for sampling variance, 158

from biased historical data, 150

from exchangeable historical data, 150

in hierarchical models, 167

indifference, 161

invariance arguments, 158

lump and smear, 161, 163

misconceptions about, 73

multiple experts, 142

non-informative, *see* reference prior distribution

normal, 62, 139

normal approximation to, 146

not uniform under transformation, 158

objective, *see* reference prior distribution

'power' prior for discounting historical evidence, 151, 153, 230

reference, *see* reference prior distribution

required to obtain a significant result, 75

robust approach, 166

sceptical, *see* sceptical prior distribution

sensitivity analysis, 165

transforming histogram, 146

use of external evidence, 148

using databases, 150

prior elicitation

bias in subjects, 147

biased choice of subjects, 147

calibrated judgements, 141

CHART trials, 143

computer-based, 142

critique of, 147

for log(hazard), 327

for log(hazard ratio), 144, 198

for log(odds ratio), 69, 255

for random-effects variability, 168, 332

in gastric cancer trial, 198

informal discussion, 141

methods for, 141

multiple experts, 142

opinion pooling, 141

potential biases in, 141

questionnaire, 142, 144

statistical aspects, 140

structured interviewing, 141

timing, 147

prior odds, 52

prior to posterior analysis, 52

probabilistic sensitivity analysis

using Monte Carlo methods, 105

probability, 10

and physical symmetries, 50

axioms, 10, 11

conditional, 11

degree of belief, 11

density, 14

distribution function, 15

'extending the conversation', 11

frequentist, 10

marginalisation, 11

odds, 12

posterior, 52

prior, 52

subjective, 10, 50

subjective, historical development, 50–1

- Bernoulli, *see* Bernoulli distribution
- beta, *see* beta distribution
- bivariate normal, *see* bivariate normal distribution
- chi-squared, *see* chi-squared distribution
- gamma, *see* gamma distribution
- half-normal, *see* half-normal distribution
- log-normal, *see* log-normal distribution
- normal, *see* normal distribution
- root-inverse-gamma, *see* root-inverse-gamma distribution
- Student's *t*, *see* Student's *t* distribution
- uniform, *see* uniform distribution
- probability distributions
 - as prior distributions, 34
 - as sampling distributions, 32
 - binary, 14–15
 - continuous, 15
 - discrete, 15
 - importance of in Bayesian approach, 9
 - improper, 15
 - parametric, 17
 - proper, 15
- probability interval, *see* credible interval
- probability of net benefit in cost-effectiveness analysis, 324
- professional equipoise, 188
- profile likelihood, 94, 102
 - to eliminate nuisance parameters, 100
- proportion
 - example of inference on, 124, 128, 134, 242, 260, 294, 297
- proportional hazards assumption, 27
- pseudo-trial, 160
- publication bias, 271
- quality weights, 152, 330
- quality-adjusted life-years (QALYs), 326
- Racine, A., 51
- random-effects model, *see* hierarchical model, 91–2
- random-effects variability
 - DuMouchel prior, 173, 273
 - gamma prior, 170, 251, 273
 - half-normal prior, 272, 289
 - in meta-analysis, 274
 - normal prior, 332
 - prior elicitation, 168
 - prior for, 167
 - profile likelihood for, 97, 102
 - reference prior distribution, 170
 - root-inverse-gamma prior, 170
 - sensitivity to prior, 272
 - uniform prior, 171, 238, 260, 272, 276, 280, 285, 319
 - uniform shrinkage prior, 172, 272
- random variables, 14
 - Bayes theorem for, 15
 - conditional independence, 17–18
 - correlation, 16
 - covariance, 16
 - expectation, 16
 - 'extending the conversation', 15
 - independent and identically distributed (i.i.d.), 17
 - marginalisation, 15
 - mean, 17
 - standard deviation, 16
- randomisation
 - arguments for, 187
 - when ethical, 187–8
- randomised controlled trials (RCTs), 181–265
 - adaptive designs, 182, 235
 - and observational studies, 251
 - Bayes theorem and interpretation, 74
 - cluster randomisation, 227
 - combined with other data, 285
 - conditional power, 191
 - crossover trials, 237
 - data-dependent allocation, 235
 - databases, 187, 251
 - dose-finding study, 236
 - epidemiology of, 74
 - equivalence trials, 237
 - ethics and randomisation, 187
 - factorial designs, 241
 - historical controls, 228
 - inference or decision?, 182
 - multi-centre analysis, 227
 - multiple endpoints, 228
 - multiple treatments, 228
 - multiplicity, 227
 - N-of-1 trials, 237
 - null hypothesis, 184
 - Phase I, 181, 242, 242
 - Phase II, 181, 236, 243
 - Phase III, 181
 - Phase IV, 181, 244
 - power, *see* power
 - range of equivalence,

- randomised controlled trials (RCTs) (*cont.*)
 - sample size, *see* sample size, 201
 - subset analysis, 227
 - uncertainty principle, 188
- range of equivalence, 185
 - changing during trial, 186, 208
 - elicitation, 185
 - for N-of-1 trials, 238
 - in CALGB trial, 224
 - in ECMO trial, 231
- ranking, 260
- rate ratio, *see* log(rate ratio)
- reasonable behaviour, axioms of, 50
- reference prior distribution
 - difficulty in specifying, 157–8
 - for normal likelihood, 62, 68
 - for random-effects variability, 170
 - giving standardised likelihood, 69
- registry database, 252
- regression to the mean, 259
- regulation, 343–44
 - decision theory, 343
 - devices, 344
 - pharmaceuticals, 343
- relative betting odds, *see* Bayes factor
- relative risk, 23
- reporting Bayesian analyses, 113
- research planning
 - pharmaceutical industry, 336
 - public sector, 335
- Rhame, F., 142, 188
- root-inverse-gamma distribution
 - as prior for random-effects variability, 170
 - definition and uses, 40
- sample size, 189
 - and power, 190
 - classical approach, 32
 - Fisherian approach, 190
 - Neyman–Pearson approach, 190
- sampling to a foregone conclusion, 162
- sampling variances
 - likelihood for, 284
- sceptical prior distribution, 148
 - and monitoring trials, 205, 243
 - critical, 77, 99
 - for assessing credibility of claim, 75
 - in B-14 trial, 216
 - in CHART trials, 160
 - role in confirmatory studies, 224
 - suggested form, 160
 - when interpreting GREAT trial, 72
- schools of Bayesian statistics, 112
- ‘second-order’ uncertainty in cost-effectiveness analysis, 322
- Senn, S., 63, 147, 181
- sensitivity, 53
- sensitivity analysis, 139
 - to alternative likelihoods, 276
 - to alternative priors, 95, 233, 273, 291, 320
 - to discordant data, 297
 - to discount rates, 334
 - to prior in GREAT trial, 72
 - to quality weights, 333
- sequential analysis, 124
 - criticism of, 126
- sequential trials, *see* monitoring trials
- sequential use of Bayes theorem, 80
- Sheiner, L., 127
- shrinkage, *see* hierarchical model, 94, 172
- Simon, R., 91
- spatial correlation, 252
- specificity, 52
- stakeholders
 - in evaluations, 51
 - in cost-effectiveness analysis, 306
 - role in future developments, 350
- standard deviation, 16
- stochastic curtailment, *see* interim power, 211
- stopping boundaries
 - Bayesian and classical, 208–7
- Stroke Prevention Policy Model, 329
- Student’s *t* distribution
 - definition and uses, 43–4
- subjective prior distribution, *see* prior elicitation
- subset analysis, 227
- sumatriptan, 80
- survival data, 27
- systolic blood pressure, 63, 67
- traditional inference, *see* classical inference
- Transcan Breast Scanner, 344
- Tukey, J., 167
- Turbuhaler (asthma treatment), 316
- Turing, A., 52
- Type I and II errors
 - Bayesian criticism of, 127
- Type I error, 74, 122, 190
- Type II error, 74, 122

- uncertainty interval, *see* credible interval
- uncertainty principle, Bayesian approach
 - to formalising, 188
- uniform distribution
 - as prior for proportion, 60
 - definition and uses, 38–9
- uniform shrinkage prior
 - for random-effects variability, 172, 272
- unit normal loss function, 338
- Urbach, P., 187
- Urokinase Pulmonary Embolism Trial, 163
- utility, *see* decision theory

- value of perfect information, 337
- variance, 16
 - conditional, 17, 312
 - iterated, 16, 81, 84, 324
 - of $O - E$, 29–30
- weight of evidence, 52
- White, I., 188, 203
- WinBUGS
 - example of use, 202, 241, 242, 260, 271–2, 277, 280, 284, 291, 294, 295, 313, 316, 328, 333, 339
 - introduction, 106
 - use in cost-effectiveness analysis, 311

- You, 50, 57
- Yusuf, S., 99